Abstract

A cross sectional study was conducted to explore the possible derangements in placental insulin signaling and also to investigate the presence or absence of maternal systemic insulin resistance in different types of hypertensive disorders of pregnancy (HDP).

Study Design: Healthy pregnant women (n=32) and pregnant women with gestational hypertension (GH) (n=18), late onset Pre-eclampsia (LP) (n=18) and early onset Pre-eclampsia (EP) (n=19) were recruited for the study. Maternal venous blood and placental samples were collected from the study subjects at 35±7 weeks of gestation. Insulin resistance parameters such as fasting glucose, fasting insulin, homeostatic model assessment of insulin resistance, beta cell function and insulin sensitivity and glycated hemoglobin were estimated in the maternal venous blood samples. Placental protein expressions of insulin signaling molecules were analyzed by western blotting method.

Results: Maternal venous blood insulin resistance parameters were not significantly different between the study groups. However, placental content of phospho insulin receptor beta was significantly decreased in GH, LP and EP groups in comparison to controls. We also found a significant decrease in placental protein expression of phosphatidyl inositol 3-kinase p85 alpha in LP group when compared to other groups.

• 1.   Shah S, Gupta A. Hypertensive disorders of pregnancy. Cardiol Clin. 2019 Aug;37(3):345–54.
• 2.   Lo JO, Mission JF, Caughey AB. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol. 2013 Apr;25(2):124–32.
• 3.   World Health Organization. Maternal mortality in 2000: estimates developed by WHO, UNICEF and UNFPA.
• 4.   Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014 Jun;2(6):e323–33.
• 5.   Osungbade KO, Ige OK. Public health perspectives of pre-eclampsia in developing countries: implication for health system strengthening. J Pregnancy. 2011;2011:481095.
• 6.   Shen M, Smith GN, Rodger M, White RR, Walker MC, Wen SW. Comparison of risk factors and outcomes of gestational hypertension and pre-eclampsia. PLoS One. 2017;12(4):e0175914.
• 7.   Amaral LM, Wallace K, Owens M, LaMarca B. Pathophysiology and current clinical management of pre-eclampsia. Curr Hypertens Rep. 2017 Aug;19(8):61.
• 8.   Melamed N, Ray JG, Hladunewich M, Cox B, Kingdom JC. Gestational hypertension and pre-eclampsia: are they the same disease? J Obstet Gynaecol Can. 2014 Jul;36(7):642–7.
• 9.   E G, Akurati L, Radhika K. Early onset and late onset pre-eclampsia-maternal and perinatal outcomes in a rural teritiary health center. Int J Reprod Contracept Obstet Gynecol. 2018 May 26;7(6):2266–9.
• 10.   Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of hypertension during pre-eclampsia linking placental ischemia with endothelial dysfunction. Hypertension. 2001 Sep;38(3 Pt 2):718–22.
• 11.   Illsley NP, Baumann MU. Human placental glucose transport in fetoplacental growth and metabolism. Biochim Biophys Acta Mol Basis Dis. 2020 Feb 1;1866(2):165359.
• 12.   Ruiz-Palacios M, Ruiz-Alcaraz AJ, Sanchez-Campillo M, Larqué E. Role of insulin in placental transport of nutrients in gestational diabetes mellitus. Ann Nutr Metab. 2017;70(1):16–25.
• 13.   Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001 Dec 13;414(6865):799–806.
• 14.   Scioscia M, Gumaa K, Kunjara S, Paine MA, Selvaggi LE, Rodeck CH, et al. Insulin resistance in human preeclamptic placenta is mediated by serine phosphorylation of insulin receptor substrate-1 and -2. J Clin Endocrinol Metab. 2006 Feb;91(2):709–17.
• 15.   Ferreira GD, Orcy RB, Martins-Costa SH, Ramos JGL, Brum IS, Corleta H von E, et al. Insulin stimulation of Akt/PKB phosphorylation in the placenta of pre-eclampsia patients. Sao Paulo Med J. 2011 Dec;129(6):387–91.
• 16.   Xue P, Fan W, Diao Z, Li Y, Kong C, Dai X, et al. Up-regulation of PTEN via LPS/AP-1/NF-$\kappa$B pathway inhibits trophoblast invasion contributing to pre-eclampsia. Mol Immunol. 2020;118:182–90.
• 17.   Kaaja R, Laivuori H, Laakso M, Tikkanen MJ, Ylikorkala O. Evidence of a state of increased insulin resistance in pre-eclampsia. Metab Clin Exp. 1999 Jul;48(7):892–6.
• 18.   Martinez Abundis E, Gonzalez Ortiz M, Quiñones Galvan A, Ferrannini E. Hyperinsulinemia in glucose-tolerant women with pre-eclampsia. A controlled study. Am J Hypertens. 1996 Jun;9(6):610–4.
• 19.   Stefanović M, Vukomanović P, Milosavljević M, Kutlesić R, Popović J, Tubić-Pavlović A. Insulin resistance and C-reactive protein in pre-eclampsia. Bosn J Basic Med Sci. 2009 Aug;9(3):235–8.
• 20.   Bartha JL, Romero-Carmona R, Torrejon-Cardoso R, Comino-Delgado R. Insulin, insulin-like growth factor-1, and insulin resistance in women with pregnancy-induced hypertension. Am J Obstet Gynecol. 2002 Sep;187(3):735–40.
• 21.   Salamalekis E, Vitoratos N, Makrakis E, Mastorakos G, Eleftheriadis M, Creatsas G. No association between insulin resistance and pre-eclampsia. J Matern Fetal Neonatal Med. 2005 Aug;18(2):113–5.
• 22.   American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122–31.
• 23.   von Dadelszen P, Magee LA, Roberts JM. Subclassification of pre-eclampsia. Hypertens Pregnancy. 2003;22(2):143–8.
• 24.   HOMA2 calculator: download [Internet]. [cited 2020 Jun 29].
• 25.   Mlinar B, Marc J, Janež A, Pfeifer M. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta. 2007 Jan 1;375(1):20–35.
• 26.   Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest. 2000 Jul 15;106(2):165–9.
• 27.   Chen Z, Liu W, Sun X, Zhu L. Clinical study on the association between pregnancy-induced hypertension and insulin resistance. Exp Ther Med. 2017 May;13(5):2065–70.

Data Sharing Statement

Funding